{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:07:20Z","timestamp":1786975640712,"version":"build-2736575974"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Cerebrospinal fluid (CSF) and plasma biomarkers can detect biological evidence of Alzheimer disease (AD), but their use in low-resource environments and among minority ethnic groups is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess validated plasma biomarkers for AD among adults of Caribbean Hispanic ethnicity.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this decision analytical modeling study, adults were recruited between January 1, 2018, and April 30, 2022, and underwent detailed clinical assessments and venipuncture. A subsample of participants also consented to lumbar puncture. Established CSF cut points were used to define AD biomarker-positive status, allowing determination of optimal cut points for plasma biomarkers in the same individuals. The performance of a panel of 6 plasma biomarkers was then assessed with respect to the entire group. Data analysis was performed in January 2023.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Main outcomes were the association of plasma biomarkers amyloid-\u03b2 1-42 (A\u03b242), amyloid-\u03b2 1-40 (A\u03b240), total tau (T-tau), phosphorylated tau181 (P-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) with AD diagnosis. These biomarkers allow assessment of amyloid (A), neurofibrillary degeneration (T), and neurodegeneration (N) aspects of AD. Statistical analyses performed included receiver operating characteristics, Pearson and Spearman correlations,\n t<\/jats:italic>\n tests, and Wilcoxon rank-sum, chi-square, and Fisher exact tests.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n Exposures included age, sex, education, country of residence, apolipoprotein-\u03b54 (\n APOE-\u03b54<\/jats:italic>\n ) allele number, serum creatinine, blood urea nitrogen, and body mass index.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This study included 746 adults. Participants had a mean (SD) age of 71.0\u2009(7.8) years, 480 (64.3%) were women, and 154 (20.6%) met clinical criteria for AD. Associations were observed between CSF and plasma P-tau181 (\n r<\/jats:italic>\n \u2009=\u2009.47 [95% CI, 0.32-0.60]), NfL (\n r<\/jats:italic>\n \u2009=\u20090.57 [95% CI, 0.44-0.68]), and P-tau181\/A\u03b242 (\n r<\/jats:italic>\n \u2009=\u20090.44 [95% CI, 0.29-0.58]). For AD defined by CSF biomarkers, plasma P-tau181 and P-tau181\/A\u03b242 provided biological evidence of AD. Among individuals judged to be clinically healthy without dementia, biomarker-positive status was determined by plasma P-tau181 for 133 (22.7%) and by plasma P-tau181\/A\u03b242 for 104 (17.7%). Among individuals with clinically diagnosed AD, 69 (45.4%) had plasma P-tau181 levels and 89 (58.9%) had P-tau181\/A\u03b242 levels that were inconsistent with AD. Individuals with biomarker-negative clinical AD status tended to have lower levels of education, were less likely to carry\n APOE-\u03b54<\/jats:italic>\n alleles, and had lower levels of GFAP and NfL than individuals with biomarker-positive clinical AD.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study, plasma P-tau181 and P-tau181\/A\u03b242 measurements correctly classified Caribbean Hispanic individuals with and without AD. However, plasma biomarkers identified individuals without dementia with biological evidence of AD, and a portion of those with dementia whose AD biomarker profile was negative. These results suggest that plasma biomarkers can augment detection of preclinical AD among asymptomatic individuals and improve the specificity of AD diagnosis.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.8214","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:33:10Z","timestamp":1681993990000},"page":"e238214","source":"Crossref","is-referenced-by-count":39,"title":["Evaluation of Plasma Biomarkers for A\/T\/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity"],"prefix":"10.1001","volume":"6","author":[{"given":"Lawrence S.","family":"Honig","sequence":"first","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Universidad Pedro Henr\u00edquez Urena, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Suk","family":"Kang","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Universidad Pedro Henr\u00edquez Urena, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Reyes-Dumeyer","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Piriz","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belisa","family":"Soriano","sequence":"additional","affiliation":[{"name":"Universidad Pedro Henr\u00edquez Urena, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahaira","family":"Franco","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Corominas, Santiago, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoraida Dominguez","family":"Coronado","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Gregorio Hernandez, Puerto Plata, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Recio","sequence":"additional","affiliation":[{"name":"Center for Diagnosis, Advanced Medicine and Telemedicine, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diones Rivera","family":"Mej\u00eda","sequence":"additional","affiliation":[{"name":"Universidad Pedro Henr\u00edquez Urena, Santo Domingo, Dominican Republic"},{"name":"Center for Diagnosis, Advanced Medicine and Telemedicine, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Medrano","sequence":"additional","affiliation":[{"name":"Pont\u00edficia Universidad Cat\u00f3lica Madre y Maestra, Santiago, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael A.","family":"Lantigua","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Department of Medicine, Vagelos College of Physicians and Surgeons, New York Presbyterian Hospital, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Teich","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Department of Neurology, Vagelos College of Physicians and Surgeons, New York Presbyterian Hospital, Columbia University, New York, New York"},{"name":"Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[{"name":"Department of Neurology, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mayeux","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"G. H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Universidad Pedro Henr\u00edquez Urena, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"3","key":"zoi230262r1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"zoi230262r2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease.","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"zoi230262r3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u00df42\/A\u00df40 and A\u00df42\/A\u00df38 ratios: better diagnostic markers of Alzheimer disease.","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"zoi230262r4","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","article-title":"Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration.","volume":"98","author":"Mattsson-Carlgren","year":"2022","journal-title":"Neurology"},{"issue":"12","key":"zoi230262r5","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease.","volume":"11","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"issue":"11","key":"zoi230262r6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/acn3.v7.11","article-title":"Amyloid-\u00df PET and CSF in an autopsy-confirmed cohort.","volume":"7","author":"Reimand","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"zoi230262r7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","article-title":"Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.","volume":"11","author":"Lle\u00f3","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"zoi230262r8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"zoi230262r9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/acn3.v8.1","article-title":"Plasma phosphorylated tau181 and neurodegeneration in Alzheimer\u2019s disease.","volume":"8","author":"Hansson","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"zoi230262r10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes.","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi230262r11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41398-021-01709-9","article-title":"Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer\u2019s amyloid, tau and FDG PET status.","volume":"11","author":"Shen","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"9","key":"zoi230262r12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol"},{"issue":"6","key":"zoi230262r13","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"11","key":"zoi230262r14","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease.","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"zoi230262r15","first-page":"569","article-title":"Classification of Alzheimer diagnosis from ADNI plasma biomarker data.","volume":"2013","author":"Mo","year":"2013","journal-title":"ACM Conf Bioinform Comput Biol Biomed Inform (2013)"},{"issue":"4","key":"zoi230262r16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","article-title":"Factors affecting A\u00df plasma levels and their utility as biomarkers in ADNI.","volume":"122","author":"Toledo","year":"2011","journal-title":"Acta Neuropathol"},{"issue":"7","key":"zoi230262r17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community.","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"zoi230262r18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.clinthera.2021.05.005","article-title":"Effect of social determinants of health on cognition and risk of Alzheimer disease and related dementias.","volume":"43","author":"Majoka","year":"2021","journal-title":"Clin Ther"},{"issue":"4","key":"zoi230262r19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/acn3.2018.5.issue-4","article-title":"Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer\u2019s disease.","volume":"5","author":"Vardarajan","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"zoi230262r20","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/jnnp-2021-326603","article-title":"Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.","volume":"92","author":"Alcolea","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"zoi230262r21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi230262r22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.v17.8","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study.","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi230262r23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/jnnp-2022-329663","article-title":"Plasma GFAP in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study.","volume":"94","author":"O\u2019Connor","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"zoi230262r24","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.v14.1","article-title":"Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer\u2019s disease and vascular pathology.","volume":"14","author":"Shir","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"issue":"6","key":"zoi230262r25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/alz.v18.6","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease.","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi230262r26","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u00df but not tau pathology in Alzheimer\u2019s disease.","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"4","key":"zoi230262r27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease.","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi230262r28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/ADR-210302","article-title":"Plasma neurofilament light and future declines in cognition and function in Alzheimer\u2019s disease in the FIT-AD trial.","volume":"5","author":"Li","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"issue":"1","key":"zoi230262r29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13195-021-00944-y","article-title":"Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.","volume":"13","author":"Marks","year":"2021","journal-title":"Alzheimers Res Ther"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803961\/honig_2023_oi_230262_1681223843.61364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:33:16Z","timestamp":1681993996000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.8214","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]}}}